Last reviewed · How we verify
Imx-110
At a glance
| Generic name | Imx-110 |
|---|---|
| Sponsor | Immix Biopharma Australia Pty Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- IMX-110 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imx-110 CI brief — competitive landscape report
- Imx-110 updates RSS · CI watch RSS
- Immix Biopharma Australia Pty Ltd portfolio CI